Galway, Ireland, April 3 – AOTI Ltd. , along with its exclusive US distribution partner Pro2Med, announced today that it will showcase its revolutionary wound care products and present multiple clinical research papers on the benefits of its novel topical oxygen therapy at the upcoming SAWC meeting in Orlando, Florida from April 17- 20, 2010.
“The annual SAWC meeting is one of the pre-eminent wound care educational programs” stated Wayne Wrolstad, President of Sales for Pro2Med “providing AOTI and Pro2Med an ideal venue to demonstrate the true value of its revolutionary wound care products to more than 2,000 physicians, podiatrists, nurses, therapists, and researchers from throughout the world.”
Mike Griffiths, President and CEO of AOTI ltd. added “The multiple clinical research papers being presented on our behalf further demonstrate the tremendous wound healing benefits of Topical Wound Oxygen therapy and that adding this novel therapy to existing wound care best practices will not only reduce the total cost of care, but more importantly improve the patient’s quality of life.”
AOTI is founded on a decade of experience in providing innovative solutions to resolve severe and chronic wounds worldwide. Our products reduce healthcare costs and improve the quality of life for patients with these debilitating illnesses. Our patented non-invasive Topical Wound Oxygen (two2) therapy is unsurpassed in fully closings Diabetic, Venous and Pressure ulcers alike. AOTI is a private company based in Galway, Ireland with offices throughout the globe. For more information, see www.aotinc.net.